Drugs / YKYY025
YKYY025
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07694557 Comparator | Jul 2026 → Jul 2028 expected | respiratory syncytial virus infectious disease | Youcare Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YKYY025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07694557 ↗ |
| Known as | YKYY025 for injection | “intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 for injection” NCT07694557 ↗ |
| Known as | YKYY025 Injection | “A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection” NCT07694557 ↗ |
| Modality | Messenger RNA (mRNA) | “Respiratory Syncytial Virus mRNA Vaccine YKYY025 Injection” NCT07694557 ↗ |
| Route | Intramuscular | “intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 for injection” NCT07694557 ↗ |